MicroRNA-138 regulates DNA damage response in small cell lung cancer cells by directly targeting H2AX

Cancer Investigation

Volumn 33, Issue 4, 2015, Pages 126-136

  Yang, Huan ^a,b   Luo, Jinwen ^c   Liu, Zhiguang ^b   Zhou, Rui ^a   Luo, Hong ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b HUNAN NORMAL UNIVERSITY   (China)

^c HUNAN CHILDREN'S HOSPITAL   (China)

Author keywords

Cell growth; H2AX; MiR 138; Small cell lung cancer

Indexed keywords

HISTONE H2AX; MICRORNA; MICRORNA 138; TUMOR MARKER; UNCLASSIFIED DRUG; H2AFX PROTEIN, HUMAN; HISTONE; MIRN138 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; CANCER GROWTH; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DOWN REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SMALL CELL LUNG CANCER; TUMOR GROWTH; UPREGULATION; GENETICS; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ADULT; AGED; CELL LINE, TUMOR; DNA DAMAGE; HISTONES; HUMANS; LUNG NEOPLASMS; MICRORNAS; MIDDLE AGED; SMALL CELL LUNG CARCINOMA;

EID: 84929996220     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2015.1006329     Document Type: Article

References (46)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. vanMeerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet 2011;378:1741-1755.
3. Roberti A, La Sala D, Cinti C. Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drugresistant tumors: current views and new therapeutic prospective. J Cell Physiol 2006;207:571-581.
4. Govindan R, Page N, Morgensztern D, Read W, Tierney R, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24: 4539-4544.
5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297.
6. Trang P, Weidhaas JB, Slack FJ. MicroRNAs as potential cancer therapeutics. Oncogene 2008;27(Suppl 2):S52-S57.
7. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009;137:1005-1017.
8. Chen P, Zeng M, Zhao Y, Fang X. Upregulation of Limk1 caused bymicroRNA-138 loss aggravates themetastasis of ovarian cancer by activation of Limk1/cofilin signaling. Oncol Rep. 2014
9. Golubovskaya VM, Sumbler B, Ho B, Yemma M, CanceWG.MiR-138 andMiR-135 directly target focal adhesion kinase, inhibit cell invasion, and increase sensitivity to chemotherapy in cancer cells. Anticancer Agents Med Chem 2014;14:18-28.
10. Han L, Zhang G, Zhang N, Li H, Liu Y, et al. Prognostic potential of microRNA-138 and its target mRNA PDK1 in sera for patients with non-small cell lung cancer. Med Oncol 2014;31:129.
11. Lal A, Pan Y, Navarro F, Dykxhoorn DM, Moreau L, et al. miR-24-mediated downregulation of H2AX suppresses DNA repair in terminally differentiated blood cells. Nat Struct Mol Biol 2009;16:492-498.
12. Hu H, Du L, Nagabayashi G, Seeger RC, Gatti RA. ATM is downregulated by N-Myc-regulated microRNA-421. ProcNatl Acad Sci U S A 2010;107:1506-1511.
13. Zhang X, Wan G, Mlotshwa S, Vance V, Berger FG, et al. OncogenicWip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway. Cancer Res 2010;70:7176-7186.
14. Pothof J, Verkaik NS, van IW, Wiemer EA, Ta VT, et al. MicroRNA-mediated gene silencing modulates the UV-induced DNA-damage response. EMBO J 2009;28:2090-2099.
15. Yang H, Tang Y, Guo W, Du Y, Wang Y, et al. Up-regulation of microRNA-138 induce radiosensitization in lung cancer cells. Tumour Biol 2014;35:6557-6565.
16. Wang Y, Huang JW, Li M, Cavenee WK, Mitchell PS, et al. MicroRNA-138 modulates DNA damage response by repressing histone H2AX expression. Mol Cancer Res 2011;9: 1100-1111.
17. Cozens AL, Yezzi MJ, Kunzelmann K, Ohrui T, Chin L, et al. CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cells. Am J Respir Cell Mol Biol 1994;10:38-47.
18. Zhao G, Cai C, Yang T, Qiu X, Liao B, et al. MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS One 2013;8:e53906.
19. Furuta T, Takemura H, Liao ZY, Aune GJ, Redon C, et al. Phosphorylation of histone H2AX and activation ofMre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem 2003;278:20303-20312.
20. Gangopadhyay NN, Luketich JD, Opest A, Landreneau R, Schuchert MJ. PARP inhibitor activates the intrinsic pathway of apoptosis in primary lung cancer cells. Cancer Invest 2014;32:339-348.
21. Qu A, Wang H, Li J, Wang J, Liu J, et al. Biological effects of (125)i seeds radiation on A549 lung cancer cells: G2/M arrest and enhanced cell death. Cancer Invest 2014;32:209-217.
22. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000;408:433-439.
23. Dickey JS, Redon CE, Nakamura AJ, Baird BJ, Sedelnikova OA, et al. H2AX: functional roles and potential applications. Chromosoma 2009;118:683-692.
24. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998;273:5858-5868.
25. Stucki M, Clapperton JA, Mohammad D, Yaffe MB, Smerdon SJ, et al. MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks. Cell 2005;123:1213-1226.
26. Lukas C, Melander F, Stucki M, Falck J, Bekker-Jensen S, et al. Mdc1 couples DNA double-strand break recognition by Nbs1 with its H2AX-dependent chromatin retention. EMBO J 2004;23:2674-2683.
27. Lou Z, Minter-Dykhouse K, Franco S, Gostissa M, Rivera MA, et al. MDC1 maintains genomic stability by participating in the amplification of ATM-dependent DNA damage signals. Mol Cell 2006;21:187-200.
28. Bassing CH, Chua KF, Sekiguchi J, Suh H, Whitlow SR, et al. Increased ionizing radiation sensitivity and genomic instability in the absence of histone H2AX. Proc Natl Acad Sci U S A 2002;99:8173-8178.
29. Celeste A, Petersen S, Romanienko PJ, Fernandez-Capetillo O, Chen HT, et al. Genomic instability in mice lacking histone H2AX. Science 2002;296:922-927.
30. Matthaios D, Hountis P, Karakitsos P, Bouros D, Kakolyris S. H2AX a promising biomarker for lung cancer: a review. Cancer Invest 2013;31:582-599.
31. Ye XW, Yu H, Jin YK, Jing XT, Xu M, et al. miR-138 inhibits proliferation by targeting 3-phosphoinositide-dependent protein kinase-1 in non-small cell lung cancer cells. Clin Respir J 2014;doi: 10.1111/crj.12100.
32. Long L, Huang G, Zhu H, Guo Y, Liu Y, et al. Down-regulation of miR-138 promotes colorectal cancer metastasis via directly targeting TWIST2. J Transl Med 2013;11:275.
33. Santarpia L, Calin GA, Adam L, Ye L, Fusco A, et al.AmiRNA signature associated with human metastatic medullary thyroid carcinoma. Endocr Relat Cancer 2013;20:809-823.
34. Kozinn SI, Harty NJ, Delong JM, Deliyiannis C, Logvinenko T, et al. MicroRNA profile to predict gemcitabine resistance in bladder carcinoma cell lines. Genes Cancer 2013;4:61-69.
35. Chakrabarti M, Banik NL, Ray SK. miR-138 overexpression is more powerful than hTERT knockdown to potentiate apigenin for apoptosis in neuroblastoma in vitro and in vivo. Exp Cell Res 2013;319:1575-1585.
36. Chatzimichail E, Matthaios D, Bouros D, Karakitsos P, Romanidis K, et al. gamma-H2AX: a novel prognostic marker in a prognosis prediction model of patients with early operable non-small cell lung cancer. Int J Genomics 2014;2014:160236.
37. Djuzenova CS, Elsner I, Katzer A, Worschech E, Distel LV, et al. Radiosensitivity in breast cancer assessed by the histone gamma-H2AX and 53BP1 foci. Radiat Oncol 2013;8:98.
38. Doai M, Watanabe N, Takahashi T, Taniguchi M, Tonami H, et al. Sensitive immunodetection of radiotoxicity after iodine-131 therapy for thyroid cancer using gamma-H2AX foci of DNA damage in lymphocytes. Ann Nucl Med 2013;27:233-238.
39. van Oorschot B, Hovingh SE, Rodermond H, Guclu A, Losekoot N, et al. Decay of gamma-H2AX foci correlates with potentially lethal damage repair in prostate cancer cells. Oncol Rep 2013;29:2175-2180.
40. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res 2014;42:D68-D73.
41. Park SY, Jeong HJ, Yang WM, Lee W. Implications of microRNAs in the pathogenesis of diabetes. Arch PharmRes 2013;36:154-166.
42. Aranda JF, Madrigal-Matute J, Rotllan N, Fernandez-Hernando C. MicroRNA modulation of lipid metabolism and oxidative stress in cardiometabolic diseases. Free Radic Biol Med 2013;64: 31-39.
43. Jansen F, Yang X, Hoelscher M, Cattelan A, Schmitz T, et al. Endothelial microparticle-mediated transfer of MicroRNA-126 promotes vascular endothelial cell repair via SPRED1 and is abrogated in glucose-damaged endothelial microparticles. Circulation 2013;128:2026-2038.
44. Jansen F, Yang X, Nickenig G, Werner N, Vasa-Nicotera M. Role, function and therapeutic potential of microRNAs in vascular aging. Curr Vasc Pharmacol. 2013
45. Lee HM, Nguyen DT, Lu LF.Progress and challenge ofmicroRNA research in immunity. Front Genet 2014;5:178.
46. Zhang H, Zhang H, Zhao M, Lv Z, Zhang X, et al.MiR-138 inhibits tumor growth through repression of EZH2 in non-small cell lung cancer. Cell Physiol Biochem 2013;31:56-65.